Effects of intensive blood-pressure control in type 2 diabetes mellitus.

作者:

DOI: 10.1056/NEJMOA1001286

关键词:

摘要: After 1 year, the mean systolic blood pressure was 119.3 mm Hg in intensivetherapy group and 133.5 standard-therapy group. The annual rate of primary outcome 1.87% intensive-therapy 2.09% (hazard ratio with intensive therapy, 0.88; 95% confidence interval [CI], 0.73 to 1.06; P = 0.20). rates death from any cause were 1.28% 1.19% two groups, respectively ratio, 1.07; CI, 0.85 1.35; 0.55). stroke, a prespecified secondary outcome, 0.32% 0.53% 0.59; 0.39 0.89; 0.01). Serious adverse events attributed antihypertensive treatment occurred 77 2362 participants (3.3%) 30 2371 (1.3%) (P<0.001). Conclusions In patients type 2 diabetes at high risk for cardiovascular events, targeting less than 120 Hg, as compared 140 did not reduce composite fatal nonfatal major events. (ClinicalTrials.gov number, NCT00000620.)

参考文章(18)
Effects of intensive glucose lowering in type 2 diabetes The New England Journal of Medicine. ,vol. 358, pp. 2545- 2559 ,(2008) , 10.1056/NEJMOA0802743
Terry M. Therneau, Patricia M. Grambsch, Modeling Survival Data: Extending the Cox Model ,(2000)
J. Stamler, O. Vaccaro, J. D. Neaton, D. Wentworth, , Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. ,vol. 16, pp. 434- 444 ,(1993) , 10.2337/DIACARE.16.2.434
Alberto Zanchetti, Lennart Hansson, Denis Clement, Dag Elmfeldt, Stevo Julius, Telma Rosenthal, Bernard Waeber, Hans Wedel, THE HOT INVESTIGATORS, including F Portaluppi, None, Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? Journal of Hypertension. ,vol. 21, pp. 797- 804 ,(2003) , 10.1097/00004872-200304000-00024
Andrew S Levey, Josef Coresh, Tom Greene, Lesley A Stevens, Yaping Zhang, Stephen Hendriksen, John W Kusek, Frederick Van Lente, Chronic Kidney Disease Epidemiology Collaboration*, None, Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate Annals of Internal Medicine. ,vol. 145, pp. 247- 254 ,(2006) , 10.7326/0003-4819-145-4-200608150-00004
John C. Peterson, Blood Pressure Control, Proteinuria, and the Progression of Renal Disease Annals of Internal Medicine. ,vol. 123, pp. 754- 762 ,(1995) , 10.7326/0003-4819-123-10-199511150-00003
William C Cushman, Richard H Grimm Jr, Jeffrey A Cutler, Gregory W Evans, Sarah Capes, Marshall A Corson, Laurie S Sadler, Michael H Alderman, Kevin Peterson, Alain Bertoni, Jan N Basile, ACCORD Study Group, None, Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology. ,vol. 99, ,(2007) , 10.1016/J.AMJCARD.2007.03.005
John B Buse, ACCORD Study Group, None, Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods American Journal of Cardiology. ,vol. 99, ,(2007) , 10.1016/J.AMJCARD.2007.03.003
Lennart Hansson, Alberto Zanchetti, S George Carruthers, Björn Dahlöf, Dag Elmfeldt, Stevo Julius, Joël Ménard, Karl Heinz Rahn, Hans Wedel, Sten Westerling, THE HOT INVESTIGATORS, including F Portaluppi, None, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial The Lancet. ,vol. 351, pp. 1755- 1762 ,(1998) , 10.1016/S0140-6736(98)04311-6